News stories about Radius Health (NASDAQ:RDUS) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Radius Health earned a news sentiment score of 0.20 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 47.336881038687 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Analysts Anticipate Radius Health (RDUS) to Post -$1.40 EPS (americanbankingnews.com)
- Zacks Investment Research Upgrades Radius Health (RDUS) to Hold (americanbankingnews.com)
- Four SFU alumni-led ventures participate in RADIUS’ Slingshot Accelerator Program (sfu.ca)
- Know the Secrets in Technical Analysis of Radius Health, Inc. (RDUS) (wallstreetmorning.com)
- Growth N. V. Biotech Acquires 50,000 Shares of Radius Health (RDUS) Stock (americanbankingnews.com)
RDUS stock opened at $34.00 on Friday. The stock has a market cap of $1,608.33, a price-to-earnings ratio of -5.86 and a beta of 1.25. The company has a debt-to-equity ratio of 0.69, a current ratio of 5.04 and a quick ratio of 4.96. Radius Health has a 1 year low of $24.66 and a 1 year high of $49.16.
Radius Health (NASDAQ:RDUS) last announced its quarterly earnings data on Thursday, March 1st. The biopharmaceutical company reported ($1.59) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.43) by ($0.16). The firm had revenue of $7.66 million during the quarter, compared to the consensus estimate of $7.37 million. Radius Health’s quarterly revenue was up 666.0% compared to the same quarter last year. During the same period last year, the firm earned ($1.22) EPS. sell-side analysts forecast that Radius Health will post -5.07 earnings per share for the current year.
Several analysts recently commented on the company. Cantor Fitzgerald reaffirmed a “buy” rating and set a $58.00 price objective on shares of Radius Health in a research note on Thursday, January 18th. ValuEngine upgraded Radius Health from a “sell” rating to a “hold” rating in a report on Monday, April 2nd. Citigroup reiterated a “hold” rating and set a $43.00 target price on shares of Radius Health in a report on Monday, January 22nd. Morgan Stanley lowered their target price on Radius Health from $61.00 to $59.00 and set an “overweight” rating for the company in a report on Friday, March 23rd. Finally, Zacks Investment Research cut Radius Health from a “hold” rating to a “sell” rating in a report on Tuesday, January 2nd. Seven equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $52.10.
In related news, major shareholder Growth N. V. Biotech acquired 50,000 shares of the firm’s stock in a transaction dated Thursday, April 5th. The stock was bought at an average price of $36.58 per share, for a total transaction of $1,829,000.00. Following the acquisition, the insider now directly owns 5,903,799 shares of the company’s stock, valued at $215,960,967.42. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Growth N. V. Biotech acquired 80,000 shares of the firm’s stock in a transaction dated Friday, March 2nd. The stock was bought at an average price of $32.52 per share, with a total value of $2,601,600.00. Following the acquisition, the insider now directly owns 5,853,799 shares in the company, valued at $190,365,543.48. The disclosure for this purchase can be found here. Insiders bought a total of 205,000 shares of company stock valued at $7,009,100 in the last 90 days. 15.00% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION WARNING: This report was originally published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.thelincolnianonline.com/2018/04/15/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-radius-health-rdus-stock-price.html.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.